Hear from expert clinical nurses on the appropriate management of patients being treated for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), including discussion of monitoring adverse events, signs of progression, and overall patient quality of life. This interactive case presentation will provide you with information on evidence-based treatment strategies and enable you to apply this information in patient scenarios.
0.75 Contact Hour
Aug 30, 2017
Aug 30, 2018
Ebony Mayo, BSN, MBAEmory University
Kaitlin Kennard, BSN, RNAbramson Cancer Center of the University of Pennsylvania
- Care of patients receiving targeted agents for the treatment of CLL or iNHL
- Adverse event management for patients with CLL or iNHL
This educational activity is designed to meet the needs of oncology nurses involved in the treatment of patients with CLL and iNHL.
After successful completion of this educational activity, participants should be able to:
- Select optimal treatment options for patients with CLL and iNHL based on the accurate assessment of patient and disease characteristics
- Identify the unique features associated with the use of oral targeted therapies that have the potential to impact quality of life and adherence to therapy
- Assess the most recent clinical data focused on novel therapeutic interventions
- Evaluate strategies to mitigate treatment-related adverse events
This educational activity is supported by a grant from Gilead Sciences, Inc.
This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.
A maximum of 0.75 contact hour may be earned for successful completion of this program. The criteria for successful completion include attending the full program and completing the evaluation.
Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method. Visit www.oncc.org for complete details on oncology nursing certification.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Flowers has disclosed that he has received consulting fees from, Bayer, Celgene, Gilead Sciences, Optum Rx, Seattle Genetics, and Spectrum. He also disclosed that he has received research funding from Abbvie, Acerta, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceutical, Millennium/Takeda,Onyx Pharmaceuticals, Pharmacyclics, and Spectrum. He also received writing and publication/presentation assistance only as related to research funding for clinical trials from Abbvie, Acerta, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Millenium/Takeda, Onyx Pharmaceuticals, Pharmacyclics, and Spectrum. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Mato has disclosed that he has received consulting fees from Celgene and Gilead and received research funding from Acerta, Celgene, Pharmacyclics, and TG Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Ebony Mayo has no financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Kaitlin Kennard has disclosed receipt of consulting fees from Abbvie and Verastem. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
- Brooke Balun, NP (lead nurse planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.